Product Information
GALBRIELA 0.8-0.025 MG CHEW TB is a generic product labeled by Xiromed LLC, priced at $1.4035 per EA under NDC 70700030685. Its NADAC has been published 60 times since Aug 13, 2025.
FDA first approved this application on Apr 23, 2014. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Manufacturer
Xiromed LLCNDC
70700030685
Classification
Generic
Dosage Form
KIT
Effective Date
9/23/2026
Approval Type
Generic (ANDA)
FDA Application
ANDA203371FDA Approved
4/23/2014
TE Code
AB
On Market Since
1/29/2025
Price Statistics
The NADAC for GALBRIELA 0.8-0.025 MG CHEW TB has been published 60 times since Aug 13, 2025, and over the history we have for it it has declined 26.1%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.4035 per EA |
|---|---|
| All-time high | $1.8990 (Aug 13, 2025) |
| All-time low | $1.2570 (Aug 19, 2026) |
| 52-week high | $1.8790 |
| 52-week low | $1.2570 |
| Median price | $1.7366 |
| Average price | $1.6015 |
| Largest weekly change | -12.6% (Apr 22, 2026) |
| Weeks tracked | 60 |
| Tracking since | Aug 13, 2025 |
Generic Alternatives
The matcher finds 2 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 64% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Xiromed LLC manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
norethindrone and ethinyl estradiol and ferrous fumarate market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of GALBRIELA 0.8-0.025 MG CHEW TB?
The current National Average Drug Acquisition Cost (NADAC) for GALBRIELA 0.8-0.025 MG CHEW TB, manufactured by Xiromed LLC, is $1.4035 per EA (NDC 70700030685), effective Sep 30, 2026.
How has the price of GALBRIELA 0.8-0.025 MG CHEW TB changed over time?
Over the history we have for it, the NADAC for GALBRIELA 0.8-0.025 MG CHEW TB has declined 26.1%. It has been tracked across 60 weekly CMS publications since Aug 13, 2025.
What are the highest and lowest recorded NADAC prices for GALBRIELA 0.8-0.025 MG CHEW TB?
Since Aug 13, 2025, the NADAC for GALBRIELA 0.8-0.025 MG CHEW TB has ranged from a low of $1.2570 (Aug 19, 2026) to a high of $1.8990 (Aug 13, 2025), with a median of $1.7366 per EA.
Are there cheaper alternatives to GALBRIELA 0.8-0.025 MG CHEW TB?
Yes. 2 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, NORET-ESTR-FE 0.4-0.035(21)-75, is $0.5101 per EA — about 64% below GALBRIELA 0.8-0.025 MG CHEW TB.
Who manufactures GALBRIELA 0.8-0.025 MG CHEW TB?
GALBRIELA 0.8-0.025 MG CHEW TB (NDC 70700030685) is labeled by Xiromed LLC, and CMS classifies it as a generic product.